Biovica presents at Unicorn Summit 2017

Anders Rylander, CEO will present at the Vator Securities Unicorn Summit in Stockholm on March 7, 2017. The presentation, part of the company’s planned IPO on Nasdaq First North in March 2017, is intended for investors. The purpose of the IPO is to raise funds to initiate the commercialization phase of the company’s DiviTum™ [...]

February 23rd, 2017 15:00|News|

Biovica strengthens its management

Uppsala, Sweden, February 20, 2017. Biovica has strengthened its management team to ensure continued successful development. Cecilia Driving (CFO), Karin Mattsson (R&D Director) and Johanna Faris (Quality and Regulatory Assurance Director) have joined the company.

February 22nd, 2017 13:30|News|

New data on DiviTum will be presented at AACR

Uppsala, Sweden, February 16, 2017. The American Association for Cancer Research (AACR) Annual Meeting on April 1-5 will gather the world’s leading cancer researchers and oncologists. Together with its research partners Dana Farber Cancer Institute and the Karolinska Institute, Biovica will present new data on the company’s DiviTum™ assay as a response marker for CDK4/6 [...]

February 16th, 2017 11:30|News|

Biovica interviewed about the upcoming IPO

Anders Rylander, CEO of Biovica and Mattias Bergqvist, VP Marketing & Clinical Development discuss the challenges in cancer diagnostics, go-to-market strategies, clinical results and IPO preparations in the latest edition of Vatorpodden. The interview is available in Swedish (only)

February 3rd, 2017 14:56|News|